Compare Southwest Airlines Co (LUV) vs McKesson Corporation (MCK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Southwest Airlines Co vs McKesson Corporation — how do they compare? Southwest Airlines Co trades at $41.4 (market cap $20.41B), while McKesson Corporation trades at $921.5 (market cap $106.14B). The key difference: McKesson Corporation is far larger — about 5.2× Southwest Airlines Co's market cap, and Southwest Airlines Co pays the higher dividend (1.73%). Which is the better fit depends on your goals — on Pluang, investors hold Southwest Airlines Co for 65 Days and McKesson Corporation for 74 Days on average.
| LUV | MCK | |
|---|---|---|
Market Cap | $20.41B | $106.14B |
Volume | 4,706,365 | 794,405 |
Sector | Industrials | Health |
52-Week High | $54.80 | $995.69 |
52-Week Low | $29.67 | $725.17 |
Typical Hold Time | 65 Days | 74 Days |
Enterprise Value | $23.51B | $112.67B |
Dividend Yield | 1.73% | 0.41% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Southwest Airlines (LUV) trades at $41.36, down 2.57% with a bearish technical signal. The company shows mixed fundamentals with a P/E of 26.08 and net margin of 2.78%, while recent earnings beat expectations in Q2 2026. Cash flow trends improved significantly in 2026 projections. Analyst consensus is divided with 42% buy ratings and a $49.61 price target representing 20% upside potential.
LUV's transformation initiatives show promise with projected $2 billion EBIT from new fare structures, though high fuel costs and competitive pressures remain risks. The stock offers value with P/S of 0.73 and strong revenue growth outlook, but requires monitoring of Q3 2026 earnings due October 22 for confirmation of the turnaround trajectory.
McKesson (MCK) trades at $930.25, up 0.93% with strong bullish momentum after recent earnings beats and positive news flow. The stock shows robust technical strength with moving averages signaling bullish alignment and price trading near resistance at $926. Fundamentally, revenue growth accelerated to $359.1 billion in 2025 with consistent profitability, though thin margins remain a characteristic of the distribution business model. Recent catalyst includes the CVS Health partnership extension through 2032, reinforcing long-term revenue visibility.
Outlook remains positive with 81% analyst buy ratings and $956.43 consensus target suggesting 2.8% upside. Key opportunities include oncology/GLP-1 growth drivers and operational efficiency gains, while risks center on drug pricing pressure, policy uncertainty, and competitive threats. The company's improved cash flow generation and debt reduction support financial stability amid sector headwinds.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Southwest Airlines Co
Southwest Airlines is the largest domestic carrier in the United States, as measured by the number of originating passengers boarded. Southwest operates over 700 aircraft in an all-Boeing 737 fleet. Despite expanding into longer routes and business travel, the airline still specializes in short-haul leisure flights, using a point-to-point network. Southwest operates a low-cost carrier business model.
Read more on LUV →About McKesson Corporation
McKesson is a leading wholesaler of branded, generic, and specialty pharmaceutical products to pharmacies (retail chains, independent, and mail order), hospitals networks, and healthcare providers. Along with AmerisourceBergen and Cardinal Health, the three account for well over 90% of the U.S. pharmaceutical wholesale industry. McKesson is currently divesting from its pharmaceutical wholesale and distribution in Europe and Canada in order to redeploy capital to strategic growth areas in the U.S. (oncology network and ecosystem, and biopharma services). Additionally, the company supplies medical-surgical products and equipment to healthcare facilities and provides a variety of technology solutions for pharmacies.
Read more on MCK →
